Trial Profile
A Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4076 Tetracosasodium Following Single-ascending Dose Administration to Healthy Male Subjects
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs RG 125 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
- 26 Jan 2023 Planned End Date changed from 26 Aug 2022 to 16 Aug 2024.
- 26 Jan 2023 Status changed from completed to active, no longer recruiting.
- 14 Jun 2022 Status changed from active, no longer recruiting to completed.